EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE | A209721 | AMNEAL PHARMACEUTICALS CO GMBH
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
Gilead Sciences, Inc. et al v. Amneal Pharmaceuticals LLC 2 patentsANDA 209721emtricitabine/tenofovir disoproxil fumarate | D. Del. | 2017-07-13 | Terminated 2018-06-08 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$10.19
per ea
Lowest NADAC/Unit
$0.4566
per ea
Brand NDCs
0
Generic NDCs
2
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 69238209203EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 100-150 MG TAB | $10.19 | EA | Generic | — | 2026-04-22 |
| 69238209503EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB | $0.4566 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.